Glenmark Pharma Share Price Gains 3% After Launching World’s First Nebulised Triple Therapy for COPD

Glenmark Pharmaceuticals saw strong buying interest on Tuesday after unveiling a breakthrough treatment for Chronic Obstructive Pulmonary Disease (COPD). The company launched the world’s first nebulised, fixed-dose triple therapy, which pushed its stock up by nearly 3% to ₹1,893.60 during intraday trading.

At 11:22 AM, the stock was trading at ₹1,875.60, up 1.8% from its previous close of ₹1,842.40. In comparison, the Nifty50 index was slightly down by 9.60 points. Glenmark’s market value stood at ₹52,932 crore, and its 52-week price range is ₹1,275.50 to ₹2,284.80.

Breakthrough COPD Treatment Unveiled

Launch of Nebzmart® and Glenmark Airz®

Glenmark introduced Nebzmart® GFB Smartules® and Glenmark Airz® FB Smartules®, marking the arrival of the first-ever nebulised triple therapy for COPD patients.

The therapy combines 3 key medicines:

• Glycopyrronium
• Formoterol
• Budesonide

This combination helps open airways, reduce inflammation, and improve overall lung function.

Why This Treatment Matters

These medicines are delivered through a nebuliser, making it especially useful for patients who struggle to use regular inhalers like MDIs or DPIs. The therapy aims to simplify treatment by replacing multiple medications with a single, easy-to-use option.

Glenmark Leadership on the Innovation

Alok Malik, President & Head of India Formulations, said the new therapy reflects Glenmark’s vision of improving patient care through innovation. He noted that this launch strengthens the company's leadership in respiratory medicine and ensures more affordable, accessible treatments.

Clinical Results

Monika Tandon, Global Head of Clinical Development, highlighted that clinical trials conducted in India showed:

• Faster improvement in lung function
• Better control over breathlessness
• Good safety and tolerance

These results support its use as a stronger and simpler treatment option for COPD patients.

Read More: Adani Group and Codelco Forge Partnership to Explore Copper Projects in Chile!

Glenmark Share Price Movement

Glenmark Pharmaceuticals share price (NSE: GLENMARK) was trading at ₹1,886.20 as of 2:05 pm on November 25, up 2.38% or ₹43.80 for the day. The stock opened at ₹1,842, touched an intraday high of ₹1,893.60, and hit a low of ₹1,837. The company currently has a market capitalisation of ₹53,230 crore, a P/E ratio of 52.72, and offers a dividend yield of 0.20%. Over the past year, the stock has moved between a 52-week high of ₹2,284.80 and a 52-week low of ₹1,275.50.

Conclusion

Glenmark’s new nebulised triple therapy sets a major milestone in the treatment of COPD. With improved convenience, strong clinical outcomes, and global-first status, the launch not only boosts patient care but also strengthens investor confidence—reflected in the stock’s solid upward move.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.